Companies › Suzhou Siran Biotechnology
2 active drug programs in 2 registered trials: 2 Phase 1; Metabolic and endocrine, Infectious disease; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SA1211 injection unclear - unknown biologic | – | Phase 1 | Chronic Hepatitis B | Mar 2027 |
| SA030 Injection | – | Phase 1 | Obese | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07275918 | SA1211 injection | Phase 1 | Chronic Hepatitis B | Infectious disease | Mar 2027 |
| NCT07479862 | SA030 Injection | Phase 1 | Obese | Metabolic and endocrine | Apr 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.